Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Medchemexpress LLC FAUC 213 | 337972-47-1 | 99.9% | C18H19ClN4 | 50 MG
SDP

Catalog No. 5000354753
Encompass_Preferred

FAUC 213 is an orally active and highly selective dopamine D4 receptor complete antagonist with a Ki of 2.2 nM for hD4.4. It shows less activity on D2 and D3 receptors, with Kis of 3.4 μM and 5.3 μM respectively. This compound can cross the blood-brain barrier (BBB) and exhibits atypical antipsychotic characteristics.

  • Highly selective dopamine D4 receptor complete antagonist
  • Orally active
  • Crosses the blood-brain barrier (BBB)
  • Exhibits atypical antipsychotic characteristics
  • Inhibits p5-HT1 (Ki=1.2 μM), p5-HT2 (Ki=0.52 μM), and pα1 (Ki=0.27 μM)
  • Significantly reduces amphetamine-induced locomotor hyperactivity at 30 mg/kg
  • Restores prepulse inhibition reduction caused by apomorphine treatment at 30 mg/kg

Catalog No. 50-003-54753 Supplier Medchemexpress LLC Supplier No. HY1432750MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

FAUC 213 is an orally active and highly selective dopamine D4 receptor complete antagonist with a Ki of 2.2 nM for hD4.4. It shows less activity on D2 and D3 receptors, with Kis of 3.4 μM and 5.3 μM respectively. This compound can cross the blood-brain barrier (BBB) and exhibits atypical antipsychotic characteristics.

  • Highly selective dopamine D4 receptor complete antagonist
  • Orally active
  • Crosses the blood-brain barrier (BBB)
  • Exhibits atypical antipsychotic characteristics
  • Inhibits p5-HT1 (Ki=1.2 μM), p5-HT2 (Ki=0.52 μM), and pα1 (Ki=0.27 μM)
  • Significantly reduces amphetamine-induced locomotor hyperactivity at 30 mg/kg
  • Restores prepulse inhibition reduction caused by apomorphine treatment at 30 mg/kg

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.